Cargando…
The cost implications of the use of pegylated liposomal doxorubicin when choosing an anthracycline for the treatment of platinum-resistant ovarian cancer: A low-value intervention?
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4563795/ https://www.ncbi.nlm.nih.gov/pubmed/26425721 http://dx.doi.org/10.1016/j.gore.2015.06.009 |
| _version_ | 1782389335749820416 |
|---|---|
| author | Cohn, David E. Shimp, William S. |
| author_facet | Cohn, David E. Shimp, William S. |
| author_sort | Cohn, David E. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4563795 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | Elsevier |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-45637952015-09-30 The cost implications of the use of pegylated liposomal doxorubicin when choosing an anthracycline for the treatment of platinum-resistant ovarian cancer: A low-value intervention? Cohn, David E. Shimp, William S. Gynecol Oncol Rep Letter to the Editor Elsevier 2015-06-25 /pmc/articles/PMC4563795/ /pubmed/26425721 http://dx.doi.org/10.1016/j.gore.2015.06.009 Text en © 2015 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Letter to the Editor Cohn, David E. Shimp, William S. The cost implications of the use of pegylated liposomal doxorubicin when choosing an anthracycline for the treatment of platinum-resistant ovarian cancer: A low-value intervention? |
| title | The cost implications of the use of pegylated liposomal doxorubicin when choosing an anthracycline for the treatment of platinum-resistant ovarian cancer: A low-value intervention? |
| title_full | The cost implications of the use of pegylated liposomal doxorubicin when choosing an anthracycline for the treatment of platinum-resistant ovarian cancer: A low-value intervention? |
| title_fullStr | The cost implications of the use of pegylated liposomal doxorubicin when choosing an anthracycline for the treatment of platinum-resistant ovarian cancer: A low-value intervention? |
| title_full_unstemmed | The cost implications of the use of pegylated liposomal doxorubicin when choosing an anthracycline for the treatment of platinum-resistant ovarian cancer: A low-value intervention? |
| title_short | The cost implications of the use of pegylated liposomal doxorubicin when choosing an anthracycline for the treatment of platinum-resistant ovarian cancer: A low-value intervention? |
| title_sort | cost implications of the use of pegylated liposomal doxorubicin when choosing an anthracycline for the treatment of platinum-resistant ovarian cancer: a low-value intervention? |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4563795/ https://www.ncbi.nlm.nih.gov/pubmed/26425721 http://dx.doi.org/10.1016/j.gore.2015.06.009 |
| work_keys_str_mv | AT cohndavide thecostimplicationsoftheuseofpegylatedliposomaldoxorubicinwhenchoosingananthracyclineforthetreatmentofplatinumresistantovariancanceralowvalueintervention AT shimpwilliams thecostimplicationsoftheuseofpegylatedliposomaldoxorubicinwhenchoosingananthracyclineforthetreatmentofplatinumresistantovariancanceralowvalueintervention AT cohndavide costimplicationsoftheuseofpegylatedliposomaldoxorubicinwhenchoosingananthracyclineforthetreatmentofplatinumresistantovariancanceralowvalueintervention AT shimpwilliams costimplicationsoftheuseofpegylatedliposomaldoxorubicinwhenchoosingananthracyclineforthetreatmentofplatinumresistantovariancanceralowvalueintervention |